Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.

Hdl Handle:
http://hdl.handle.net/10147/252818
Title:
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.
Authors:
Manecksha, Rustom P; Nason, Gregory J; Cullen, Ivor M; Fennell, Jérôme P; McEvoy, Elizabeth; McDermott, Ted; Flynn, Robert J; Grainger, Ronald; Thornhill, John A
Affiliation:
Department of Urology, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland. rustom.manecksha@gmail.com
Citation:
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men. 2012, 2012:650858 ScientificWorldJournal
Journal:
TheScientificWorldJournal
Issue Date:
2012
URI:
http://hdl.handle.net/10147/252818
DOI:
10.1100/2012/650858
PubMed ID:
22645441
Abstract:
We aimed to compare infection rates for two 3-day antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy (TRUSgbp) and demonstrate local microbiological trends. In 2008, 558 men and, in 2009, 625 men had TRUSgpb. Regimen 1 (2008) comprised 400 mg Ofloxacin immediately before biopsy and 200 mg 12-hourly for 3 days. Regimen 2 (2009) comprised Ofloxacin 200 mg 12-hourly for 3 days commencing 24 hours before biopsy. 20/558 (3.6%) men had febrile episodes with regimen 1 and 10/625 (1.6%) men with regimen 2 (P = 0.03). E. coli was the most frequently isolated organism. Overall, 7/13 (54%) of positive urine cultures were quinolone resistant and (5/13) 40% were multidrug resistant. Overall, 5/9 (56%) patients with septicaemia were quinolone resistant. All patients were sensitive to Meropenem. There was 1 (0.2%) death with regimen 1. Commencing Ofloxacin 24 hours before TRUSgpb reduced the incidence of febrile episodes significantly. We observed the emergence of quinolone and multidrug-resistant E. coli. Meropenem should be considered for unresolving sepsis.
Item Type:
Article
Language:
en
ISSN:
1537-744X

Full metadata record

DC FieldValue Language
dc.contributor.authorManecksha, Rustom Pen_GB
dc.contributor.authorNason, Gregory Jen_GB
dc.contributor.authorCullen, Ivor Men_GB
dc.contributor.authorFennell, Jérôme Pen_GB
dc.contributor.authorMcEvoy, Elizabethen_GB
dc.contributor.authorMcDermott, Teden_GB
dc.contributor.authorFlynn, Robert Jen_GB
dc.contributor.authorGrainger, Ronalden_GB
dc.contributor.authorThornhill, John Aen_GB
dc.date.accessioned2012-11-20T16:19:20Z-
dc.date.available2012-11-20T16:19:20Z-
dc.date.issued2012-
dc.identifier.citationProspective study of antibiotic prophylaxis for prostate biopsy involving >1100 men. 2012, 2012:650858 ScientificWorldJournalen_GB
dc.identifier.issn1537-744X-
dc.identifier.pmid22645441-
dc.identifier.doi10.1100/2012/650858-
dc.identifier.urihttp://hdl.handle.net/10147/252818-
dc.description.abstractWe aimed to compare infection rates for two 3-day antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy (TRUSgbp) and demonstrate local microbiological trends. In 2008, 558 men and, in 2009, 625 men had TRUSgpb. Regimen 1 (2008) comprised 400 mg Ofloxacin immediately before biopsy and 200 mg 12-hourly for 3 days. Regimen 2 (2009) comprised Ofloxacin 200 mg 12-hourly for 3 days commencing 24 hours before biopsy. 20/558 (3.6%) men had febrile episodes with regimen 1 and 10/625 (1.6%) men with regimen 2 (P = 0.03). E. coli was the most frequently isolated organism. Overall, 7/13 (54%) of positive urine cultures were quinolone resistant and (5/13) 40% were multidrug resistant. Overall, 5/9 (56%) patients with septicaemia were quinolone resistant. All patients were sensitive to Meropenem. There was 1 (0.2%) death with regimen 1. Commencing Ofloxacin 24 hours before TRUSgpb reduced the incidence of febrile episodes significantly. We observed the emergence of quinolone and multidrug-resistant E. coli. Meropenem should be considered for unresolving sepsis.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to TheScientificWorldJournalen_GB
dc.titleProspective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland. rustom.manecksha@gmail.comen_GB
dc.identifier.journalTheScientificWorldJournalen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.